Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University Medical Centre Ljubljana.
Recruitment status was  Not yet recruiting
Information provided by:
University Medical Centre Ljubljana Identifier:
First received: July 17, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
The investigators will compare doxycycline and ceftriaxone in treatment of patients with suspected early Lyme neuroborreliosis and normal CSF cell count. The study hypothesis is that the efficacy and adverse effects of both antibiotics are comparable.

Condition Intervention
Suspected Early Lyme Neuroborreliosis
Drug: doxycycline
Drug: ceftriaxone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count.

Resource links provided by NLM:

Further study details as provided by University Medical Centre Ljubljana:

Primary Outcome Measures:
  • Objective sequelae and post-treatment subjective symptoms in patients treated for suspected early Lyme neuroborreliosis with normal CSF cell count with doxycycline or ceftriaxone for 14 days. [ Time Frame: 1 year follow-up ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 200
Study Start Date: July 2009
Estimated Study Completion Date: November 2011
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: LNB-doxycycline Drug: doxycycline
100 mg bid, 14 days
Active Comparator: LNB-ceftriaxone Drug: ceftriaxone
2g x 1 iv, 14 days


Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age >15 years
  • erythema migrans in 4 months period before neurologic symptoms
  • normal CSF cell count
  • absence of more defined clinical symptoms or signs for CNS involvement (radicular pain, meningeal signs, peripheral facial palsy).

Exclusion Criteria:

  • pregnancy
  • lactation
  • allergy on doxycycline and ceftriaxone
  • immune deficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00942006

Contact: Katarina Ogrinc, MD PhD +386 1 522 4217
Contact: Franc Strle, PhD MD +386 1 522 2110

UMC Ljubljana, Department of Infectious Diseases
Ljubljana, Slovenia, 1525
Sponsors and Collaborators
University Medical Centre Ljubljana
Study Chair: Franc Strle, MD PhD UMC Ljubljana
  More Information

Responsible Party: Katarina Ogrinc MD PhD, UMC Ljubljana Identifier: NCT00942006     History of Changes
Other Study ID Numbers: LNB-doxy-ceftriaxone 
Study First Received: July 17, 2009
Last Updated: July 17, 2009
Health Authority: Slovenia: Ethics Committee

Keywords provided by University Medical Centre Ljubljana:
Lyme neuroborreliosis
Lyme borreliosis
erythema migrans
doxycycline treatment
ceftriaxone treatment
subjective symptoms

Additional relevant MeSH terms:
Lyme Neuroborreliosis
Bacterial Infections
Borrelia Infections
Central Nervous System Bacterial Infections
Central Nervous System Diseases
Central Nervous System Infections
Gram-Negative Bacterial Infections
Lyme Disease
Nervous System Diseases
Spirochaetales Infections
Tick-Borne Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents processed this record on May 23, 2016